Gilde Biotech hires

KS Biomedix CEO Steven Powell has joined the Netherlands-based venture capital firm as a director and partner.

Gilde Biotechnology and Nutrition, the venture capital unit of Dutch private equity firm Gilde Investment Management, has recruited Steven Powell to the firm’s pan-European team. Powell becomes a partner and director at the Dutch firm.


Powell joins Gilde from KS Biomedix Holdings plc, a biopharmaceutical company listed on the London Stock Exchange where he was CEO. At KS Biomedix, he was responsible for building a pipeline of late stage clinical development products, licensing and corporate acquisition. He also led two financing rounds. Prior to this, he was CEO at Actinova, a subsidiary of the Swedish biopharmaceutical company, Active Biotech AB.


“We are delighted that Steven is joining our team,” said Marc Olivier Perret, director at Gilde Biotechnology & Nutrition Fund. “His strong technology background, diverse operational experience with biotech companies at all stages of development, broad network in the industry and experience in interacting with investors will be a valuable asset to us and the companies in our investment portfolio.”


Gilde Biotechnology & Nutrition Fund is managed by Gilde Investment Management, the private equity firm based in the Netherlands.  Gilde manages a number of different funds, including the Gilde Buyout and IT funds. The Biotechnology & Nutrition Fund is focused on early stage investments in the fields of discovery, development & delivery of biopharmaceutical products. The fund received a total of E127m subscribed by European investors who include Rabobank, European Investment Fund, Syngenta, Banco Sabadell, Fonditel, Fibanc and Lagun-Aro. Recent investments by the fund include Pieris (Germany), Ablynx (Belgium) and Innate Pharma (France).